Treatment for Lung

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Levine Cancer Institute, Charlotte, NC
Lung+1 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to understand the recurrence of cancer for metastatic non-small cell lung cancer (mNSCLC) patients that have been treated with pembrolizumab either alone or together with chemotherapy as the first line of treatment.

Eligible Conditions

  • Lung

Treatment Effectiveness

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: 6 months

6 months
Change in Acquisition of T Cell Clones
Change in Demographic Information ctDNA Association
Change in Sustained Cytotoxic Immune Effector Activation
Change in ctDNA Presence
Change in ctDNA Tumor Mutations
Change in immune related Biomarkers
Change in immune related Biomarkers - age, gender, smoking status, type of Non-small cell lung cancer (NSCLC)
Identification of Biomarker Signature appearance or absence
To compare the change of blood immune related biomarkers

Trial Safety

Trial Design

0 Treatment Group

70 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Levine Cancer Institute · Charlotte, NC
Photo of levine cancer institute  1Photo of levine cancer institute  2Photo of levine cancer institute  3
2014First Recorded Clinical Trial
3 TrialsResearching Lung
79 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to understand and comply with study procedures for the entire length of the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.